Venus Remedies secures marketing authorization for chemotherapy drug 'Docetaxel'

01 Jun 2023 Evaluate

In a decisive step towards making its entire oncology product portfolio available in Saudi Arabia, Venus Remedies has secured a marketing authorization from the largest market in the Gulf Cooperation Council (GCE) region for Docetaxel, a widely used chemotherapy drug.

The development comes three months after the company received good manufacturing practices (GNP) certification from the Saudi Food and Drug Authority (SFDA) for all its production facilities at its unit in Baddi, Himachal Pradesh.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. 


Venus Remedies Share Price

721.40 -34.35 (-4.55%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×